Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]
, 2019 Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C +29 more
core
The gut microbiota and immune checkpoint inhibitors. [PDF]
, 2018 Although immunotherapy has been remarkably effective across multiple cancer types, there continues to be a significant number of non-responding patients. A possible factor proposed to influence the efficacy of immunotherapies is the gut microbiome.
Daud, Adil, Humphries, Audrey
core +1 more source
Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]
, 2019 The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core +1 more source
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance [PDF]
, 2019 Programmed cell death protein (PD-1) and its ligands play a fundamental role in the evasion of tumor cells from antitumor immunity. Less well appreciated is the fact that the PD-1/PD-L1 axis also regulates antiviral immune responses and is therefore ...
Raftery, Martin J., Schönrich, Günther
core +1 more source
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]
, 2018 Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim +5 more
core +1 more source
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]
, 2017 Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello +3 more
core +1 more source
Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. [PDF]
, 2018 Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC).
Dicker, Adam P., Lu, Bo, McCall, Neal S.
core +1 more source
Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model [PDF]
, 2020 Combination Therapies of Guadecitabine and Immune Checkpoint Inhibitors in a Murine Triple-Negative Breast Cancer Model Jamie-Jean Gilmer, Depts. of Biology and Chemistry, with Dr. Sarah Golding, Dept.
Gilmer, Jamie-Jean
core +1 more source
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. [PDF]
, 2019 Solid tumours are infiltrated by effector T cells with the potential to control or reject them, as well as by regulatory T (Treg) cells that restrict the function of effector T cells and thereby promote tumour growth1.
Cadilha, Bruno L +16 more
core +2 more sources
PD-1 signaling promotes control of chronic viral infection by restricting type-I-interferon-mediated tissue damage [PDF]
, 2019 Immune responses are essential for pathogen elimination but also cause tissue damage, leading to disease or death. However, it is unclear how the host immune system balances control of infection and protection from the collateral tissue damage.
Egawa, Takeshi +2 more
core +1 more source